PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMCB PharmaCyte Biotech, Inc.

Post-Mkt 09-04 16:18:16 EDT

0.4865

-0.0048

-0.98%

盘后0.4865

+0.00000.00%

16:10 EDT

High0.5009	Low0.4855	Vol44.46K
Open0.5000	D1 Closing0.4913	Amplitude3.13%
Mkt Cap5.22M	Tradable Cap4.90M	Total Shares10.74M
T/O21.85K	T/O Rate0.44%	Tradable Shares10.07M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMCB","market":"US","secType":"STK","nameCN":"PharmaCyte Biotech, Inc.","latestPrice":0.4865,"timestamp":1788552000000,"preClose":0.4913,"halted":0,"volume":44455,"hourTrading":{"tag":"盘后","latestPrice":0.4865,"preClose":0.4865,"latestTime":"16:10 EDT","volume":4,"amount":1.946,"timestamp":1788552604405,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009769997964583811,"floatShares":10069000,"shares":10735649,"eps":-2.769999,"marketStatus":"Post-Mkt","change":-0.0048,"latestTime":"09-04 16:18:16 EDT","open":0.5,"high":0.5009,"low":0.4855,"amount":21854,"amplitude":0.031345,"askPrice":0.52,"askSize":100,"bidPrice":0.4482,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.769999,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788566400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.4913,"postHourTrading":{"tag":"盘后","latestPrice":0.4865,"preClose":0.4865,"latestTime":"16:10 EDT","volume":4,"amount":1.946,"timestamp":1788552604405,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.51769,"impliedVol":5.2972,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/PMCB/","defaultTab":"news","newsList":[{"id":"2655981255","title":"PharmaCyte Net Loss Widens to $19.42 Million in FY26; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981255?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:20","pubTimestamp":1785360011,"startTime":"0","endTime":"0","summary":"PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenuePharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL4JYXWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","PMCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624682962","title":"PharmaCyte Biotech shareholders approved 2 million-share increase to 2022 equity plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624682962","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624682962?lang=en_us&edition=fundamental","pubTime":"2026-04-03 04:22","pubTimestamp":1775161341,"startTime":"0","endTime":"0","summary":"PharmaCyte Biotech held its annual shareholder meeting on March 30, 2026, for fiscal year ended April 30, 2026.Shareholders backed an amendment to 2022 Equity Incentive Plan, lifting share pool for future awards by 2,000,000 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL908DLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMCB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pharmacyte.com","stockEarnings":[{"period":"1week","weight":-0.0905},{"period":"1month","weight":-0.1825},{"period":"3month","weight":-0.2981},{"period":"6month","weight":-0.3475},{"period":"1year","weight":-0.489},{"period":"ytd","weight":-0.3214}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.275918},{"month":2,"riseRate":0.5,"avgChangeRate":0.084919},{"month":3,"riseRate":0.25,"avgChangeRate":-0.129966},{"month":4,"riseRate":0.5,"avgChangeRate":-0.039461},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.070214},{"month":6,"riseRate":0.444444,"avgChangeRate":0.043254},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.118517},{"month":8,"riseRate":0.111111,"avgChangeRate":-0.167391},{"month":9,"riseRate":0.555556,"avgChangeRate":0.061535},{"month":10,"riseRate":0.25,"avgChangeRate":-0.073172},{"month":11,"riseRate":0.25,"avgChangeRate":-0.078728},{"month":12,"riseRate":0.25,"avgChangeRate":-0.023475}],"exchange":"NASDAQ","name":"PharmaCyte Biotech, Inc.","nameEN":"PharmaCyte Biotech, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PharmaCyte Biotech, Inc.,PMCB,PharmaCyte Biotech, Inc.股票,PharmaCyte Biotech, Inc.股票老虎,PharmaCyte Biotech, Inc.股票老虎国际,PharmaCyte Biotech, Inc.行情,PharmaCyte Biotech, Inc.股票行情,PharmaCyte Biotech, Inc.股价,PharmaCyte Biotech, Inc.股市,PharmaCyte Biotech, Inc.股票价格,PharmaCyte Biotech, Inc.股票交易,PharmaCyte Biotech, Inc.股票购买,PharmaCyte Biotech, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PharmaCyte Biotech, Inc.(PMCB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PharmaCyte Biotech, Inc.(PMCB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction